TECHNOLOGY PLATFORM

The OsteoActivator^TM technology is based on the use of the biodegradable carrier PLGA which enables sustained and controlled release of ancillary amounts of the low molecular weight bone healing compounds testosterone and alendronate. Testosterone will enhance osteoblast activity whereas alendronate will inhibit osteoclast activity. Importantly, these compounds act synergistically, resulting in a net shift towards an increased formation of new bone. Upon release of the bone healing compounds over a 4–6-week period, bone remodeling will recover and continue normally and, hence, the newly formed bone will remain intact. Because Osteo-Pharma’s technology includes PLGA as a carrier for sustained and controlled release of the bone healing compounds, safety issues are not anticipated when using the OsteoActivator^TM technology- based products. Indeed, extensive preclinical studies have confirmed the absence of adverse effects at any of the dosages tested. 

The products Osteo-Pharma is focusing on include:

OsteoActivator-C

Orthopedic implants coated with OsteoActivator^TM coating to enhance osseo-integration.